- エボラの流行 2014年 アフリカ PART11©2ch.net
253 ：名無しさん＠お腹いっぱい。[sage]：2015/02/05(木) 22:56:04.67 ID:yZkHVjmR - http://jp.reuters.com/article/businessNews/idJPKBN0L827C20150204
富士フイルムのエボラ薬、臨床試験で期待持てる結果＝フランス
2015年 02月 5日 03:28 JST
［４日 ロイター］ - フランス政府は４日、西アフリカのギニアで行われているエボラ出血熱治療に関する
臨床試験について、これまでのところ期待が持てる結果が出ており、患者の回復過程が速まっているようだ
との見解を示した。
昨年１２月中旬に始まった臨床試験では、富士フイルム(4901.T: 株価, ニュース, レポート)グループの
富山化学工業が開発したインフルエンザ薬「アビガン」（一般名：ファビピラビル）が使用されている。
大統領府は「臨床試験では期待が持てる結果が出ており、成人、子どもともに死亡数が低下しているほか、
回復過程が速まっている」と指摘。これまでに成人と子どもの計８０人が治療を受けたとした。
ーーーーーーーー
なお、富士フイルムの株価は、-8円だった。
| - エボラの流行 2014年 アフリカ PART11©2ch.net
254 ：名無しさん＠お腹いっぱい。[sage]：2015/02/05(木) 23:29:47.65 ID:yZkHVjmR - Ebola Drug Aids Some in a Study in West Africa
http://www.nytimes.com/2015/02/05/science/ebola-drug-has-encouraging-early-results-and-questions-follow.html?_r=1
FEB. 4, 2015
For the first time, a drug is showing promising signs of effectiveness in Ebola patients participating in
a study. The medicine, which interferes with the virus’s ability to copy itself, seems to have halved
mortality ― to 15 percent, from 30 percent ― in patients with low to moderate levels of Ebola in
their blood, researchers have found. It had no effect in patients with more virus in their blood,
who are more likely to die.
The drug, approved as an influenza treatment in Japan last year, was generally well tolerated.
“The results are encouraging in a certain phase of the disease,” Dr. Sakoba Keita, director of disease
control for the Guinean Ministry of Health, said in a telephone interview. The drug is being tested in
Guinea, one of the three West African countries most affected by the Ebola crisis.
The details of the early findings have not yet been announced, but they raise questions about which
patients, if any, outside the study should be offered treatment with the drug, favipiravir. “These are
very difficult, agonizing decisions,” said Susan Ellenberg, a professor of biostatistics at the University of
Pennsylvania’s Perelman School of Medicine, who was not involved in the research. She cautioned that
early results were sometimes not borne out.
| - エボラの流行 2014年 アフリカ PART11©2ch.net
255 ：名無しさん＠お腹いっぱい。[sage]：2015/02/05(木) 23:32:41.88 ID:yZkHVjmR - 続き
The drug has been provided on an emergency basis to Ebola patients in European countries, but not in
Africa. The Japanese maker of the drug announced in October that it had 20,000 courses of treatment
in stock. The epidemic is now ebbing but is not over. The World Health Organization on Wednesday
reported 124 new cases in Guinea, Sierra Leone and Liberia in the week that ended on Sunday,
warning of an increased geographical spread in Guinea and a rise in new cases in all three countries
for the first time this year.
Early reports of the interim results of the drug trial have created unanticipated complications, delaying
the testing of at least one other therapy as researchers reconsidered plans and some doctors pressed to
make favipiravir more widely available.
Researchers and health authorities have been quietly debating whether and when to release the
preliminary results of the study. The dilemmas they face echo those from the early years of the AIDS
epidemic. Because mortality was so high in a disease with no proven treatment, there was demand to
provide experimental therapies to everyone.
The results for the drug favipiravir are based on an analysis of 69 patients older than 14 who have
received it at two sites in Guinea since December. The survival rates of those with low to moderate
levels of virus in their blood were significantly better than those of patients previously treated at a
center run by Doctors Without Borders in Gueckedou, Guinea.
| - エボラの流行 2014年 アフリカ PART11©2ch.net
256 ：名無しさん＠お腹いっぱい。[sage]：2015/02/05(木) 23:34:40.15 ID:yZkHVjmR - 続き
Caroline Guele, 31, a rice farmer who lost two children and her husband to Ebola, received the drug in
January at the site run by the Alliance for International Medical Action soon after she developed
symptoms. She said she believed it contributed to her survival. “When I heard I could take the
medicine, I actually prayed to God it would help me,” she said in a telephone interview Wednesday.
In a typical drug study, participants would be randomly assigned to take the drug or not, and the
outcomes would be compared to see if the drug made a difference. However, because Ebola is so
deadly and there is no known treatment aside from supportive care, all patients in the study were
provided with the treatment. Fluctuating death rates during the current epidemic have complicated
researchers’ efforts to assess whether the new drug should be credited with the reduced mortality.
The drug was expected to be most effective in patients receiving it within two to three days of showing
symptoms, similar to antiviral treatments for influenza. However, most study participants arrived at the
Ebola treatment units later in their illnesses, a median of five days after their symptoms began, so
results were analyzed instead in terms of the approximate levels of virus in the blood.
Independent boards charged with monitoring the drug trial detected the encouraging findings and
recommended that they be made public. Results were submitted for review to the Conference on
Retroviruses and Opportunistic Infection, which will take place in Seattle at the end of the month. A
draft of an abstract of the findings was reviewed by The New York Times.
“With Ebola, there’s precious little good news,” said Dr. Susan Shepherd, who served as medical
coordinator at a treatment unit run by the Alliance for International Medical Action, one of two sites
where the drug was tested. (The other was a facility run by Doctors Without Borders.)
Dr. Shepherd added, “There will, I think, be an enormous pressure and desire to offer the treatment more broadly.”
|
|